Innovative Drug Solutions for Difficult‑to‑Express and Complex Proteins

Innovative Drug Solutions for Difficult‑to‑Express and Complex Proteins
Product Description

Integrated development and manufacturing solutions combining molecular engineering, vector optimization, host cell engineering, and customized process development. The platform delivers high titers for mAb production, and DTEasy™ strategies have demonstrated significant yield improvements across various difficult‑to‑express protein types. Covers upstream/downstream process development and GMP manufacturing support.

Read more Show less

Canton Biologics

  • Country/Region:
    Hong Kong
  • Founded:
    2016
  • On CPHI since:
    2026
  • Employees:
    250 - 499
Company types
CMO/CDMO
View company profile
Categories
more categories Show less
Specifications
  • CAS Registry Number
    N/A
  • Details
    Monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), fusion proteins, recombinant proteins; mammalian (CHO) and microbial expression systems; addresses challenges such as low expression, instability, aggregation, and cellular stress.

  • Selling Points
    Proprietary DTEasy™ toolbox; high‑performance CHOzen® host; supports from early R&D to commercial production.

  • Model
    DTEasy™ Toolbox + CHOzen® Expression Platform
  • Supplied from
    China
  • Measured In
    Container
More specifications Fewer specifications

Canton Biologics

  • Country/Region:
    Hong Kong
  • Founded:
    2016
  • On CPHI since:
    2026
  • Employees:
    250 - 499
Company types
CMO/CDMO
View company profile

More Products from Canton Biologics (5)

  • Biologics Development Solutions for Companion Animal Therapeutics

    Product Biologics Development Solutions for Companion Animal Therapeutics

    Leverages advanced expression technologies, optimised vectors, and flexible bioprocessing platforms to deliver scalable and cost‑efficient solutions tailored to companion animal biologics. Supports from early development to GMP manufacturing, with customisation for veterinary specific requirements.

  • Biomedical and Healthcare Recombinant Protein Solutions

    Product Biomedical and Healthcare Recombinant Protein Solutions

    Combines molecular engineering, host cell optimisation, expression system development, and process optimisation to address complex protein structures. The IgMax® platform enables production of pentameric IgM at high expression levels, with near‑complete pentamer assembly and excellent purity after downstre...
  • Integrated Biosimilar CMC Solutions – from Development to Commercial Manufacturing

    Product Integrated Biosimilar CMC Solutions – from Development to Commercial Manufacturing

    End‑to‑end biosimilar development from cell line construction to PPQ and commercial batches. The integrated platform enables a fast development timeline, supports global GMP requirements, and offers competitive cost of goods. Includes DS/DP manufacturing, analytical testing, quality support, and technology...
  • Integrated CMC Solutions for Advanced Therapies

    Product Integrated CMC Solutions for Advanced Therapies

    Customised CMC development and manufacturing for a broad range of advanced biologic modalities. Services include process development, analytical characterisation, scale‑up, and GMP manufacturing, tailored to the characteristics and development stage of each modality.

  • Recombinant Antigen and Vaccine Solutions for Livestock & Poultry

    Product Recombinant Antigen and Vaccine Solutions for Livestock & Poultry

    Combines advanced expression technologies with optimised vectors, cell culture processes, and downstream purification for high‑productivity and cost‑efficient manufacturing. Multimerisation and nanoparticle platforms enable the design of defined antigen structures in various multimeric forms, supporting ne...